NYSE:ENZ

Enzo Biochem (ENZ) Stock Forecast, Price & News

$2.18

-0.02 (-0.91%)

(As of 06/9/2023 ET)

Compare

Today's Range: $2.17
▼
$2.21
50-Day Range: $2.18
▼
$2.66
52-Week Range: $1.00
▼
$2.75

Volume: 66,922 shs
Average Volume: 111,297 shs
Market Capitalization: $108.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

June 8, 2023 | finance.yahoo.com

Enzo Biochem, Inc.'s (NYSE:ENZ) Popularity With Investors Is Under Threat From Overpricing

June 4, 2023 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) Stock Price Crosses Above 200-Day Moving Average of $1.83

June 10, 2023 | Behind the Markets (Ad)

[Strong Buy Alert] Is this laser stock in your portfolio?

🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.

June 1, 2023 | yahoo.com

Enzo Biochem says ransomware attack exposed clinical test data of 2.5 million patients

May 31, 2023 | seekingalpha.com

Enzo Biochem says ransomware attack exposed patient info, Social Security numbers

May 22, 2023 | finanznachrichten.de

Enzo Biochem, Inc.: Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

May 22, 2023 | finance.yahoo.com

Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

May 18, 2023 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

June 10, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 14, 2023 | finance.yahoo.com

Enzo Biochem Insiders Added US$11m Of Stock To Their Holdings \

May 13, 2023 | marketwatch.com

Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Forecast 2023-2031 with Size and Share

May 4, 2023 | marketwatch.com

Global Blood Screening Market by [2023-2029] with Revenue Outsourcing

May 3, 2023 | marketwatch.com

Wound Healing Assay Kits Market Analysis and Forecast to 2031

May 3, 2023 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.

April 28, 2023 | marketwatch.com

2023-2030 Non-Radioactive Nucleic Acid Labeling Product Market Growth Developments with Latest Updates

April 28, 2023 | msn.com

Enzo Biochem in Farmingdale to Lay Off 247 Employees

April 28, 2023 | marketwatch.com

Global Monensin Market Share 2023-2030 with On-going Demand Status

April 24, 2023 | finance.yahoo.com

Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders

April 23, 2023 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

April 19, 2023 | marketwatch.com

Flow Cytometry Market | Latest Updates and Forecast to 2031

April 17, 2023 | finance.yahoo.com

Enzo Biochem (NYSE:ENZ) shareholders have endured a 58% loss from investing in the stock five years ago

April 15, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)

April 13, 2023 | americanbankingnews.com

Comparing Akumin (NASDAQ:AKU) & Enzo Biochem (NYSE:ENZ)

April 7, 2023 | marketwatch.com

8-K: ENZO BIOCHEM INC

April 7, 2023 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

March 31, 2023 | marketwatch.com

Nucleic Acid Labeling Market 2023 Growth, Trend and Outlook till 2031

March 26, 2023 | americanbankingnews.com

Enzo Biochem (NYSE:ENZ) vs. Aclarion (NASDAQ:ACON) Head-To-Head Contrast

See More Headlines

ENZ Price History

30 days | 90 days | 365 days | Advanced Chart

ENZ Company Calendar

Last Earnings: 3/20/2023
Today: 6/10/2023
Fiscal Year End: 7/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:ENZ
CUSIP: N/A
CIK: 316253
Web: www.enzo.com
Phone: (212) 583-0100
Fax: 212-679-7999
Employees: 451
Year Founded: 1976

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,260,000.00
Net Margins: -43.44%
Pretax Margin: -43.44%
Return on Equity: -67.73%
Return on Assets: -36.44%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 1.13
Quick Ratio: 0.64

Sales & Book Value

Annual Sales: $107.07 million
Price / Sales: 1.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.12 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 49,660,000
Free Float: 41,965,000
Market Cap: $108.26 million
Optionable: Optionable
Beta: 1.04

Social Links

Key Executives

Hamid Erfanian
Chief Executive Officer & Director

Kara Cannon
Chief Operating Officer

Patricia Eckert
Chief Financial Officer

Dieter Schapfel
Chief Medical Director

Matthew Kupferberg
Secretary & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?: Enzo Biochem's stock was trading at $1.43 at the beginning of 2023. Since then, ENZ shares have increased by 52.4% and is now trading at $2.18.
View the best growth stocks for 2023 here.
Are investors shorting Enzo Biochem?: Enzo Biochem saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,220,000 shares, an increase of 8.9% from the April 15th total of 1,120,000 shares. Based on an average daily volume of 849,700 shares, the days-to-cover ratio is currently 1.4 days. Currently, 3.7% of the shares of the company are short sold.
View Enzo Biochem's Short Interest.
How were Enzo Biochem's earnings last quarter?: Enzo Biochem, Inc. (NYSE:ENZ) posted its quarterly earnings data on Monday, March, 20th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter. The medical research company earned $16.34 million during the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 67.73% and a negative net margin of 43.44%.
What other stocks do shareholders of Enzo Biochem own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).
What is Enzo Biochem's stock symbol?: Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?: Enzo Biochem's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.58%), Dimensional Fund Advisors LP (3.06%), BlackRock Inc. (2.86%), Roumell Asset Management LLC (1.82%), Potomac Capital Management Inc. (1.57%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf and Kara Cannon.
View institutional ownership trends.
How do I buy shares of Enzo Biochem?: Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enzo Biochem's stock price today?: One share of ENZ stock can currently be purchased for approximately $2.18.
How much money does Enzo Biochem make?: Enzo Biochem (NYSE:ENZ) has a market capitalization of $108.26 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.
How many employees does Enzo Biochem have?: The company employs 451 workers across the globe.
How can I contact Enzo Biochem?: Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial